Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Sean Nolan
AddedFeb 13, 2024
UpdatedJun 28, 2026
Sean Nolan

Sean Nolan

Board Member, Taysha Gene Therapies

CrunchbaseLinkedInThe Org

Sean Nolan's Career

Taysha Gene Therapies
Taysha Gene Therapies

Dallas, TX, US

Board Member· Board
Affinia Therapeutics
Affinia Therapeutics

Waltham, MA, US

Board Member· Board
Encoded Therapeutics
Encoded Therapeutics

South San Francisco, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Sean Nolan's Career

Taysha Gene Therapies
Taysha Gene Therapies
Public$468M812020Dallas, TX, US
Board Member· Board

Leadership at Taysha Gene Therapies

Sukumar NagendranSukumar NagendranBoard Member
Melissa A. EllisMelissa A. EllisBoard Member
Phillip DonenbergPhillip DonenbergBoard Member
R A SessionR A SessionFounder
Affinia Therapeutics
Affinia Therapeutics
Series B$170M752019Waltham, MA, US
Board Member· Board

Leadership at Affinia Therapeutics

Rick ModiRick ModiBoard Member
Botond RoskaBotond RoskaCo-Founder
David GrayzelDavid GrayzelBoard Member
Luk VandenbergheLuk VandenbergheBoard Member
Aaron TwardAaron TwardCo-Founder
Rob AboudRob AboudCo-Founder

Similar to Affinia Therapeutics

Affini-T TherapeuticsAffini-T TherapeuticsWatertown, MA, UST-Cell Therapiesest. 2021Affini-T TherapeuticsWatertown, MA, US · est. 2021

Affini-T Therapeutics: Pioneering cancer treatment with innovative T-cell therapies using gene editing.

Late Stage Private · $175M175
Frontera TherapeuticsFrontera TherapeuticsBedford, MA, USGene Therapyest. 2019Frontera TherapeuticsBedford, MA, US · est. 2019

Frontera Therapeutics: Affordable, high-quality gene therapy solutions for global health.

Series B · $160M175
AffaMed TherapeuticsAffaMed TherapeuticsNew York City, NY, USPharmaceuticalsest. 2019AffaMed TherapeuticsNew York City, NY, US · est. 2019

AffaMed Therapeutics: A clinical-stage biopharmaceutical company innovating transformative drugs.

Series B · $170M175
Encoded Therapeutics
Encoded Therapeutics
Series D$239.1M2002014South San Francisco, CA, US
Board Member· Board

Leadership at Encoded Therapeutics

Karan TakharKaran TakharBoard Member
Kartik RamamoorthiKartik RamamoorthiBoard Member
John StuelpnagelJohn StuelpnagelBoard Member
Stephanie TagliatelaStephanie TagliatelaBoard Member

Sean Nolan's Similar Executives & Operators

Willix HalimWillix HalimCEO · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailKen KutaragiKen KutaragiBoard Member · RakutenTakashi MitachiTakashi MitachiBoard Member · Rakuten

People Similar to Sean Nolan

Michael ColaMichael ColaBoard Member · Avalo TherapeuticsBrian ArnbergerBrian ArnbergerCo-Founder · AtheraxonChad HoskinsChad HoskinsCEO · Axon TherapiesJohn M LeonardJohn M LeonardBoard Member · Intellia TherapeuticsStephen FarrStephen FarrBoard Member · Flow Pharma